Kenvue (KVUE) Projected to Post Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $3.69 billion for the quarter. Kenvue has set its FY 2025 guidance at 1.440-1.469 EPS.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.61 on Thursday. The company has a market cap of $45.30 billion, a price-to-earnings ratio of 44.55, a PEG ratio of 2.62 and a beta of 1.02. The business has a 50 day moving average price of $23.07 and a 200 day moving average price of $22.47. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. Kenvue’s dividend payout ratio is 154.72%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KVUE. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price target on the stock. Finally, Barclays reduced their price objective on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, April 14th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus target price of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.